Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New furoxan derivatives for the treatment of ocular hypertension.
Blangetti M, Rolando B, Chegaev K, Guglielmo S, Lazzarato L, Durante M, Masini E, Almirante N, Bastia E, Impagnatiello F, Fruttero R, Gasco A. Blangetti M, et al. Among authors: impagnatiello f. Bioorg Med Chem Lett. 2017 Feb 1;27(3):479-483. doi: 10.1016/j.bmcl.2016.12.041. Epub 2016 Dec 18. Bioorg Med Chem Lett. 2017. PMID: 28027869 Free article.
NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs.
Bastia E, Toris CB, Brambilla S, Galli C, Almirante N, Bergamini MVW, Masini E, Sgambellone S, Unser AM, Ahmed F, Torrejon KY, Navratil T, Impagnatiello F. Bastia E, et al. Among authors: impagnatiello f. Invest Ophthalmol Vis Sci. 2021 Mar 1;62(3):17. doi: 10.1167/iovs.62.3.17. Invest Ophthalmol Vis Sci. 2021. PMID: 33704360 Free PMC article.
A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
Borghi V, Bastia E, Guzzetta M, Chiroli V, Toris CB, Batugo MR, Carreiro ST, Chong WK, Gale DC, Kucera DJ, Jia L, Prasanna G, Ongini E, Krauss AH, Impagnatiello F. Borghi V, et al. Among authors: impagnatiello f. J Ocul Pharmacol Ther. 2010 Apr;26(2):125-32. doi: 10.1089/jop.2009.0120. J Ocul Pharmacol Ther. 2010. PMID: 20415621
Nitric oxide (NO): an emerging target for the treatment of glaucoma.
Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E. Cavet ME, et al. Among authors: impagnatiello f. Invest Ophthalmol Vis Sci. 2014 Aug 14;55(8):5005-15. doi: 10.1167/iovs.14-14515. Invest Ophthalmol Vis Sci. 2014. PMID: 25125670 Review.
NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys.
Bastia E, Toris C, Bukowski JM, Brambilla S, Galli C, Almirante N, Bergamini MVW, Lucarini L, Navratil T, Impagnatiello F. Bastia E, et al. Among authors: impagnatiello f. J Ocul Pharmacol Ther. 2021 May;37(4):215-222. doi: 10.1089/jop.2020.0126. Epub 2021 Feb 15. J Ocul Pharmacol Ther. 2021. PMID: 33595367
47 results